Innovative Medical Technology Advances with First Patient Enrollments
Newsfile· 2024-11-12 21:00
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.co ...
Akamai Launches Cloud-Agnostic, Ready-to-Run Application Platform
Prnewswire· 2024-11-12 21:00
Solves three of the biggest challenges for greater Kubernetes adoption: skills, scale, and lock-in CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Akamai Technologies, Inc. (NASDAQ: AKAM), the cybersecurity and cloud company that powers and protects business online, today announced the Akamai App Platform, a ready-to-run solution that makes it easy to deploy, manage, and scale highly distributed applications. Akamai App Platform is a ready-to-run solution that makes it easy to deploy, manage, and scale high ...
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Prnewswire· 2024-11-12 21:00
CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference ...
ASHFORD HOSPITALITY TRUST ANNOUNCES MODIFICATION FOR MORTGAGE LOAN
Prnewswire· 2024-11-12 21:00
DALLAS, Nov. 12, 2024 /PRNewswire/ -- Ashford Hospitality Trust, Inc. (NYSE: AHT) ("Ashford Trust" or the "Company") announced today that it has successfully entered into a 90-day forbearance period for its Morgan Stanley Pool loan secured by 17 hotels. The loan had a final maturity date of November 9, 2024. The Company is in active discussions with the lender regarding a multi-year extension of the loan and expects to have that finalized during the 90-day period. "We are currently in active discussions wit ...
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
Prnewswire· 2024-11-12 21:00
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT ...
FACTORY DEMAND WEAKENS ACROSS MAJOR ECONOMIES IN OCTOBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
Prnewswire· 2024-11-12 21:00
U.S. factories cut back purchases sharply, signaling heightened risks of manufacturing weakness spilling over into the broader economy in 2025 In contrast, Chinese factories report growth following three months of shrinking input purchasing Europe's industrial recession shows no sign of abating, with German, French and Austrian producers at the heart of the downturn CLARK, N.J., Nov. 12, 2024 /PRNewswire/ -- The GEP Global Supply Chain Volatility Index — a leading indicator tracking demand conditions, short ...
HERTZ REPORTS THIRD QUARTER 2024 RESULTS
Prnewswire· 2024-11-12 21:00
"In the third quarter, we continued executing on our efforts to implement our transformation, focusing on our back-to-basics strategy to deliver sustainable, long-term returns for shareholders," said Gil West, Hertz CEO. "Our team's commitment to both our customers and our strategic objectives were evident throughout the summer. This dedication is reflective of our ongoing endeavors to improve operational performance and reposition the Company to achieve against its value proposition. There is still work to ...
Independent Proxy Advisory Firms ISS and Glass Lewis Agree Biglari Capital Has Made Compelling Case for Change at Cracker Barrel
Prnewswire· 2024-11-12 21:00
Glass Lewis Recommends that Shareholders Vote FOR Two of Biglari Capital's Nominees and ISS Recommends Shareholders Vote FOR One of Biglari Capital's Nominees Incumbent Directors Carl Berquist and Meg Crofton Have Overseen Observably Poor Performance and Significant Shareholder Value Destruction ISS and Glass Lewis Both Cite Substantial Analyst Concern Over the Company's Costly Transformation Plan Biglari Capital Urges Shareholders to Vote the GOLD Proxy Card for All Three of Its Director Nominees. San Anto ...
Millennium Spacecraft for NASA TRACERS Mission Moves to Testing Phase
Prnewswire· 2024-11-12 21:00
EL SEGUNDO, Calif., Nov. 12, 2024 /PRNewswire/ -- Millennium Space Systems, a Boeing (NYSE: BA) company, completed two spacecraft for NASA's Tandem Reconnection and Cusp Electrodynamics Reconnaissance Satellites, or TRACERS, mission, which will measure the connection between solar wind and the magnetic field surrounding Earth. Millennium Spacecraft for NASA TRACERS Mission Moves to Testing Phase Millennium Spacecraft for NASA TRACERS Mission Moves to Testing Phase "TRACERS will ultimately inform how we unde ...
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Prnewswire· 2024-11-12 21:00
Company on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 Trial designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML HOUSTON, Nov. 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-totreat tumors and viruses, t ...